Click chemistry, 3D-printing, and omics: the future of drug development

Genomics is a disruptive technology, having revealed that cancers are tremendously complex and differ from patient to patient. Therefore, conventional treatment approaches fit poorly with genomic reality. Furthermore, it is likely that this type of complexity will also be observed in other illnesses. Precision medicine has been posited as a way to better target disease-related aberrations, but developing drugs and tailoring therapy to each patient's complicated problem is a major challenge. One solution would be to match patients to existing compounds based on in silico modeling. However, optimization of complex therapy will eventually require designing compounds for patients using computer modeling and just-in-time production, perhaps achievable in the future by three-dimensional (3D) printing. Indeed, 3D printing is potentially transformative by virtue of its ability to rapidly generate almost limitless numbers of objects that previously required manufacturing facilities. Companies are already endeavoring to develop affordable 3D printers for home use. An attractive, but as yet scantily explored, application is to place chemical design and production under digital control. This could be accomplished by utilizing a 3D printer to initiate chemical reactions, and print the reagents and/or the final compounds directly. Of interest, the Food and Drug Administration (FDA) has recently approved a 3D printed drug—levetiracetam—indicated for seizures. Further, it is now increasingly clear that biologic materials—tissues, and eventually organs—can also be “printed.” In the near future, it is plausible that high-throughput computing may be deployed to design customized drugs, which will reshape medicine.

[1]  J. Lee,et al.  Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. , 2014, Cancer research.

[2]  R. Yelensky,et al.  Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms , 2014, Oncotarget.

[3]  Jeremy C. Smith,et al.  Task‐parallel message passing interface implementation of Autodock4 for docking of very large databases of compounds using high‐performance super‐computers , 2011, J. Comput. Chem..

[4]  Elçin Içten,et al.  Dropwise additive manufacturing of pharmaceutical products for melt-based dosage forms. , 2015, Journal of pharmaceutical sciences.

[5]  M. G. Finn,et al.  Click Chemistry: Diverse Chemical Function from a Few Good Reactions. , 2001, Angewandte Chemie.

[6]  Brian Derby,et al.  Printing and Prototyping of Tissues and Scaffolds , 2012, Science.

[7]  I. Tsigelny,et al.  Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer , 2015, Oncotarget.

[8]  N. Jones Science in three dimensions: The print revolution , 2012, Nature.

[9]  Philip J. Kitson,et al.  Integrated 3D-printed reactionware for chemical synthesis and analysis. , 2012, Nature chemistry.

[10]  Laura Hirshfield,et al.  Dropwise additive manufacturing of pharmaceutical products for solvent-based dosage forms. , 2014, Journal of pharmaceutical sciences.

[11]  R. Kurzrock,et al.  Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes , 2015, Cell cycle.

[12]  Jerome BaudryCorresponding authorUT,et al.  High-throughput virtual molecular docking with AutoDockCloud , 2012 .

[13]  Anthony Atala,et al.  3D bioprinting of tissues and organs , 2014, Nature Biotechnology.

[14]  Vladimir Mironov,et al.  Bioprinting living structures , 2007 .

[15]  Sally R. Ellingson,et al.  High‐throughput virtual molecular docking with AutoDockCloud , 2014, Concurr. Comput. Pract. Exp..

[16]  Jake E. Barralet,et al.  Simultaneous Immobilization of Bioactives During 3D Powder Printing of Bioceramic Drug‐Release Matrices , 2010 .